Repositioning Candidate Details

Candidate ID: R0689
Source ID: DB05061
Source Type: investigational
Compound Type: small molecule
Compound Name: GFT14
Synonyms: --
Molecular Formula: --
SMILES: --
DrugBank Description: GFT14 is a new class of medicaction for treatment of cardiometabolic disease. GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease. GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides) and on other risk factors such as hypertension or diabetes. Orally absorbed GFT14 has absolutely no structural link with current treatments for dyslipidemia (statin or fibrate based). The risks of medical interaction are weak and GFT14 may be easily combined with statins or other antidiabetic molecules (glitazones).
CAS Number: --
Molecular Weight:
DrugBank Indication: Investigated for use/treatment in cardiovascular disorders and hyperlipidemia.
DrugBank Pharmacology: --
DrugBank MoA: GFT14 is a synthetic modified triglyceride that agonizes PPAP alpha. It raises HDL-C and lowers triglycerides.
Targets: --
Inclusion Criteria: Indication associated